Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cogent Biosciences ( (COGT) ) has provided an announcement.
On November 11, 2025, Cogent Biosciences announced the pricing of its public offerings, which include 9,677,420 shares of common stock at $31.00 per share and $200 million in 1.625% convertible senior notes due 2031. The equity offering was upsized from the initially planned $200 million, and the net proceeds from both offerings are expected to be approximately $475.3 million. These funds will be used to repay existing loans and support the development and commercialization of bezuclastinib and other product candidates. The equity offering is set to close on November 13, 2025, and the convertible notes offering on November 18, 2025, with no dependency on each other’s closing.
The most recent analyst rating on (COGT) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Cogent Biosciences stock, see the COGT Stock Forecast page.
Spark’s Take on COGT Stock
According to Spark, TipRanks’ AI Analyst, COGT is a Underperform.
Cogent Biosciences is currently facing significant financial difficulties, with no recent revenue, ongoing operating losses, and negative cash flows. The technical analysis indicates a bearish trend, and the valuation is unattractive due to a negative P/E ratio and absence of dividends. These factors contribute to the lowest overall stock score, highlighting substantial risks for investors.
To see Spark’s full report on COGT stock, click here.
More about Cogent Biosciences
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. Its most advanced clinical program is bezuclastinib, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation, which is associated with systemic mastocytosis and advanced gastrointestinal stromal tumors. The company is also developing a portfolio of novel targeted therapies for other serious, genetically driven diseases.
Average Trading Volume: 2,577,628
Technical Sentiment Signal: Buy
Current Market Cap: $5.02B
For an in-depth examination of COGT stock, go to TipRanks’ Overview page.